Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anxiolytic Drugs: Benzodiazepines and Buspirone01:29

Anxiolytic Drugs: Benzodiazepines and Buspirone

443
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
443
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

69
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
69
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

102
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
102
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

125
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
125
Bipolar Disorder01:30

Bipolar Disorder

41
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
41
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

111
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
111

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ensifentrine: A Novel Option for Maintenance of Chronic Obstructive Pulmonary Disease.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians·2025
Same author

Ceftobiprole: A therapeutic update.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2025
Same author

Capivasertib.

Hospital pharmacy·2024
Same author

Zuranolone: A Narrative Review of a New Oral Treatment for Postpartum Depression.

Clinical therapeutics·2024
Same author

Rozanolixizumab: A New Therapy in the Treatment of Myasthenia Gravis.

The Annals of pharmacotherapy·2024
Same journal

Transitioning Medication-Related Home Visits to a Cognitively Accessible Digital Intervention in Home Care: A Practice Innovation Pilot.

The Senior care pharmacist·2026
Same journal

Perception of Technology to Support Medication Management Among Community-dwelling African American Older Adults.

The Senior care pharmacist·2026
Same journal

Initial Evaluation of L-mMRC Severity Tool in Staging COPD in the Skilled Nursing Setting.

The Senior care pharmacist·2026
Same journal

Beyond Resistance: Prioritizing Safety in Antimicrobial Stewardship for Older Adults.

The Senior care pharmacist·2026
Same journal

Geriatric Pharmacotherapy Case Series: GLP-1 RA for Weight Management in Older Adults.

The Senior care pharmacist·2026
Same journal

Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer's Disease: Progress and Challenges.

The Senior care pharmacist·2026
See all related articles

Related Experiment Video

Updated: May 25, 2025

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.0K

Brexpiprazole: A Balance of Risks and Benefits.

Emily M Hitt1

  • 1Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington.

The Senior Care Pharmacist
|February 27, 2025
PubMed
Summary
This summary is machine-generated.

Brexpiprazole is the first FDA-approved medication for Alzheimer's disease agitation. Clinical studies show it is a safe and effective treatment option for managing these challenging behavioral and psychological symptoms in dementia.

More Related Videos

Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

4.3K
Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

6.4K

Related Experiment Videos

Last Updated: May 25, 2025

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack
07:31

Implementation of a Real-Time Psychosis Risk Detection and Alerting System Based on Electronic Health Records using CogStack

Published on: May 15, 2020

7.0K
Self-Administration of Drugs in Mouse Models of Feeding and Obesity
03:37

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

4.3K
Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study
07:30

Brain Morphology of Cannabis Users With or Without Psychosis: A Pilot MRI Study

Published on: August 18, 2020

6.4K

Area of Science:

  • Neuroscience
  • Geriatrics
  • Pharmacology

Background:

  • Alzheimer's disease is the leading cause of dementia, often accompanied by behavioral and psychological symptoms in dementia (BPSD).
  • Managing BPSD is complex, with historically limited FDA-approved pharmacological options, leading to off-label medication use.
  • Agitation is a common and impactful BPSD, significantly affecting patient prognosis and care.

Purpose of the Study:

  • To review the clinical profile of brexpiprazole, focusing on its safety and efficacy in elderly patients.
  • To examine the Phase III studies supporting the FDA approval of brexpiprazole for Alzheimer's disease-related agitation.
  • To evaluate the potential role and impact of brexpiprazole in the therapeutic landscape for BPSD.

Main Methods:

  • Review of clinical trial data from two Phase III studies evaluating brexpiprazole for agitation in Alzheimer's disease dementia.
  • Analysis of safety, efficacy, and tolerability data in the target patient population.
  • Assessment of brexpiprazole's pharmacological properties, including its affinity for various monoaminergic receptors.

Main Results:

  • Two Phase III studies indicated that brexpiprazole is a potentially safe, effective, and well-tolerated treatment for agitation associated with Alzheimer's disease dementia.
  • Brexpiprazole demonstrated efficacy in reducing symptoms of agitation in older adults with dementia.
  • The drug's safety and tolerability profile in this population was consistent with findings in broader clinical trials.

Conclusions:

  • Brexpiprazole represents a novel, FDA-approved therapeutic option for managing agitation in Alzheimer's disease dementia.
  • While effective, careful patient assessment is crucial to balance the benefits of brexpiprazole against potential risks.
  • This approval offers a new avenue for clinicians managing the complex and multifactorial BPSD.